オメガ3処方薬の世界市場

オメガ3処方薬の世界市場は2030年までに16億米ドルに達する

2024年に13億米ドルと推定されるオメガ3処方薬の世界市場は、2030年には16億米ドルに達し、分析期間2024-2030年のCAGRは3.0%で成長すると予測されます。本レポートで分析したセグメントの1つであるバセパ薬は、CAGR 2.4%を記録し、分析期間終了時には8億2,120万米ドルに達すると予測されます。Lovaza Drugs」セグメントは、分析期間中にCAGR 3.4%の成長が見込まれます。

米国市場は3億5,680万米ドルと推定、中国はCAGR 5.5％で成長予測

米国のオメガ3処方薬市場は、2024年に3億5,680万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.5%として、2030年までに3億290万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.2%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

オメガ3処方薬の世界市場- 主要動向と促進要因のまとめ

オメガ3処方薬が心血管および代謝療法で臨床的地位を獲得しているのはなぜか？

オメガ3処方薬は、特に高トリグリセリド血症、心血管疾患（CVD）、その他の炎症に起因する慢性疾患を管理するために、医薬品業界において重要なコンポーネントとして浮上しています。栄養補助食品とは異なり、これらの医薬品は精製、濃縮され、有効性と安全性が臨床試験されており、医療介入に適した高用量のエイコサペンタエン酸（EPA）および／またはドコサヘキサエン酸（DHA）を提供しています。トリグリセリド値を低下させ、脂質プロファイルを改善し、残存する心血管リスクを軽減するそれらの役割は、高用量のイコサペントエチル（EPA）が心血管転帰に有益であることを実証したREDUCE-ITなどの大規模臨床試験で検証されています。このような知見により、オメガ3をベースとした治療薬が様々な治療ガイドラインに盛り込まれ、循環器専門医やプライマリ・ケア提供者による処方の急増に拍車がかかっています。オメガ3系薬剤は、スタチン系薬剤や他の脂質低下薬と併用できるため、複雑な脂質異常症の症例管理における価値が高まっています。さらに、オメガ3処方製剤は、関節リウマチ、慢性腎臓病、認知機能低下など、心臓の健康以外の症状にも有効であることが証明されており、その治療範囲はさらに広がっています。高齢化が進み、慢性疾患の負担が世界中で増加する中、オメガ3処方薬は単なるサプリメントとしてではなく、独自の抗炎症作用と心臓保護作用のメカニズムを持つ、エビデンスに裏打ちされた医薬品として見なされるようになってきています。

規制当局の承認と臨床試験はどのように治療用途を拡大しているのか？

規制当局の進歩やしっかりとした臨床研究は、オメガ3処方薬の市場の可能性を大きく広げています。FDAがイコサペントエチルやオメガ3酸エチルエステルなど複数のオメガ3系製剤を重度の高トリグリセリド血症に承認したことで、その治療効果が検証され、より広範な臨床採用への道が開かれました。一方、現在進行中の臨床試験では、アルツハイマー病、双極性障害、乾癬、特定のがんなどの治療へのオメガ3の潜在的な利用が検討されており、オメガ3の既知の抗炎症作用と細胞膜安定化作用が後押ししています。EUやアジア太平洋地域では、規制当局もこの動向に歩調を合わせ、高純度EPA・DHA製剤の承認や償還の拡大を認めています。製薬会社は、特にスタチン不耐性の患者や心血管リスクが残存している患者を対象に、オメガ3系薬剤の併用療法や補助的な使用法を評価するための長期的な試験への投資を増やしています。バイオアベイラビリティを高め、胃腸の副作用を最小限に抑えるために、徐放技術や新しい脂質カプセル化システムなどの知的財産戦略が追求されています。こうした開発は、オメガ3処方薬の治療領域を拡大するだけでなく、混雑している心血管系治療領域において競合他社との差別化を生み出します。規制当局がより的を絞った個別化治療の選択肢を求める中、オメガ3系医薬品は、生命を脅かす疾患の一次予防と二次予防の両方において二重の役割を果たすことから、引き続き支持を集めています。

自然で安全な治療法に対する患者の需要は、オメガ3製薬の状況を再構築しているか？

自然で忍容性が高く、科学的裏付けのある治療法に対する患者の関心の高まりは、オメガ3処方薬市場を再形成する重要な力です。多くの消費者が合成薬による長期的な副作用を警戒するようになり、特に慢性疾患の管理において、オメガ3療法はその良好な安全性プロファイルと天然由来であることから受け入れられています。この動向は、高齢者や複数の合併症を持つ患者の間で特に強く、彼らはしばしば長期的な薬理学的管理を必要とし、より穏やかで無害な治療オプションを好みます。市販の魚油サプリメントとは異なり、処方されるオメガ3系医薬品は、標準化された用量、管理された純度、臨床的に検証された結果を提供し、これらすべてが患者と医師の信頼を高めています。健康リテラシーの向上と治療決定への患者の関与により、心臓、脳、関節の健康におけるオメガ3の役割に対する認識が高まり、市場の関連性がさらに強まっています。さらに、予防ヘルスケアへのシフトは、オメガ3処方薬を心血管リスクを管理するための予防的でライフスタイルに沿ったツールとして位置づけています。遠隔医療プラットフォームと電子薬局サービスもまた、より簡単なアクセス、より広範なアウトリーチ、より良い服薬アドヒアランスに貢献しています。製薬会社は、消費者向けキャンペーン、デジタル教育、パーソナライズされたエンゲージメント戦略を通じて、このような患者の意識の高まりを活用しています。天然と医薬品の融合」という認識が広まり続ける中、オメガ3系医薬品は、従来の薬物療法とウェルネス中心の患者優先医療とのギャップを埋めつつあります。

オメガ3処方薬市場の世界的成長加速の原動力は？

オメガ3処方薬市場の成長は、臨床革新、慢性疾患の流行、規制の勢い、ヘルスケア嗜好の変化に根ざしたいくつかの要因によって牽引されています。主な成長要因のひとつは、高脂血症、糖尿病、肥満などの心血管疾患や代謝性疾患の世界の増加で、スタチン系薬剤を超える脂質低下補助療法への需要が高まっています。さらに、REDUCE-ITやJELISのような画期的な試験で良好な結果が得られたことから、EPAに着目した治療法の臨床的位置づけが強まり、循環器内科や内科での採用が広がっています。特に北米、欧州、日本では高齢者人口が拡大しており、加齢に伴うCVD、認知機能低下、炎症関連疾患の増加が需要をさらに押し上げています。商業面では、製剤技術や投与量の最適化における医薬品の技術革新により、薬剤の忍容性、バイオアベイラビリティ、コンプライアンスが向上し、治療成績の改善に繋がっています。また、新興市場における規制当局の承認の増加、保険適用率の上昇、公衆衛生キャンペーンも市場浸透を促進しています。栄養補助食品と医薬品の境界線が曖昧になりつつあることで、医薬品と栄養補助食品の提携やハイブリッド・ビジネス・モデルの門戸が開かれています。さらに、目や脳の健康から関節の可動性に至るまで、オメガ3の幅広い効能に対する認識が高まり、医師が全人的な治療計画にオメガ3を考慮するようになっています。こうした動きを総合すると、オメガ3処方薬はニッチな循環器系補助食品から、世界のヘルスケア・システム全体で主流となる多機能治療ソリューションへと押し上げられつつあります。

セグメント

医薬品（バセパ医薬品、ロバザ医薬品、その他医薬品）、流通チャネル（小売薬局、病院薬局、オンライン薬局）、用途（循環器用途、その他用途）

調査対象企業の例

• Abbott Laboratories
• Amarin Corporation plc
• Apotex Inc.
• AstraZeneca plc
• BASF SE
• Bayer AG
• Camber Pharmaceuticals, Inc.
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc（GSK）
• Grupo Ferrer Internacional, S.A.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Natrapharm, Inc.（Patriot Pharmaceutical Corp.）
• Novartis International AG
• Pfizer Inc.
• Sandoz International GmbH
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Omega 3 Prescription Drugs Market to Reach US$1.6 Billion by 2030

The global market for Omega 3 Prescription Drugs estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Vascepa Drugs, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$821.2 Million by the end of the analysis period. Growth in the Lovaza Drugs segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$356.8 Million While China is Forecast to Grow at 5.5% CAGR

The Omega 3 Prescription Drugs market in the U.S. is estimated at US$356.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$302.9 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Omega-3 Prescription Drugs Market - Key Trends & Drivers Summarized

Why Are Omega-3 Prescription Drugs Gaining Clinical Ground in Cardiovascular and Metabolic Therapy?

Omega-3 prescription drugs are emerging as a crucial component in the pharmaceutical landscape, particularly for managing hypertriglyceridemia, cardiovascular disease (CVD), and other inflammation-driven chronic conditions. Unlike dietary supplements, these drugs are purified, concentrated, and clinically tested for efficacy and safety, offering higher dosages of eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) suitable for medical intervention. Their role in reducing triglyceride levels, improving lipid profiles, and mitigating residual cardiovascular risk has been validated in large-scale clinical trials such as REDUCE-IT, which demonstrated cardiovascular outcome benefits from high-dose icosapent ethyl (EPA). These findings have driven inclusion of omega-3-based therapies in various treatment guidelines and have spurred a surge in prescriptions by cardiologists and primary care providers alike. The ability of these drugs to function alongside statins and other lipid-lowering agents enhances their value in managing complex dyslipidemia cases. Additionally, omega-3 prescription formulations have proven beneficial in conditions beyond heart health, including rheumatoid arthritis, chronic kidney disease, and cognitive decline, further expanding their therapeutic scope. With an aging population and a rising burden of chronic diseases worldwide, omega-3 prescription drugs are increasingly viewed not just as supplements, but as evidence-backed pharmaceuticals with a unique anti-inflammatory and cardioprotective mechanism of action.

How Are Regulatory Approvals and Clinical Trials Expanding Therapeutic Applications?

Regulatory advancements and robust clinical research are significantly expanding the market potential for omega-3 prescription drugs. The FDA’s approval of multiple omega-3-based formulations-such as icosapent ethyl and omega-3 acid ethyl esters-for severe hypertriglyceridemia has validated their therapeutic efficacy, opening pathways for broader clinical adoption. Meanwhile, ongoing trials are investigating their potential use in treating conditions like Alzheimer’s disease, bipolar disorder, psoriasis, and certain cancers, fueled by omega-3s' known anti-inflammatory and cell membrane-stabilizing effects. In the EU and Asia-Pacific, regulatory agencies are also aligning with this trend, granting approvals and expanding reimbursement for high-purity EPA and DHA formulations. Pharmaceutical companies are increasingly investing in long-term studies to evaluate combination therapies and adjunctive uses of omega-3 drugs, particularly in statin-intolerant patients or those with persistent residual cardiovascular risk. Intellectual property strategies, such as extended-release technologies and novel lipid encapsulation systems, are being pursued to enhance bioavailability and minimize gastrointestinal side effects. These developments not only expand the therapeutic footprint of omega-3 prescription drugs but also create competitive differentiation in an otherwise crowded cardiovascular treatment space. As regulatory bodies demand more targeted and personalized treatment options, omega-3 drugs continue to gain traction for their dual role in both primary and secondary prevention of life-threatening conditions.

Is Patient Demand for Natural and Safe Therapies Reshaping the Omega-3 Pharmaceutical Landscape?

Rising patient interest in natural, well-tolerated, and science-backed therapies is a significant force reshaping the omega-3 prescription drug market. As more consumers grow wary of long-term side effects from synthetic drugs-especially in managing chronic conditions-omega-3 therapies are being embraced for their favorable safety profiles and natural origins. This trend is particularly strong among older adults and patients with multiple comorbidities, who often require long-term pharmacological management and prefer gentler, non-toxic treatment options. Unlike over-the-counter fish oil supplements, prescription omega-3 drugs offer standardized dosages, controlled purity, and clinically validated outcomes, all of which increase patient and physician trust. The rise in health literacy and patient involvement in treatment decisions has created greater awareness of omega-3s' role in heart, brain, and joint health, further reinforcing their market relevance. Additionally, the shift toward preventive healthcare is positioning omega-3 prescription drugs as proactive, lifestyle-aligned tools for managing cardiovascular risk. Telemedicine platforms and e-pharmacy services are also contributing to easier access, broader outreach, and better medication adherence. Pharmaceutical companies are leveraging this growing patient awareness through direct-to-consumer campaigns, digital education, and personalized engagement strategies. As the perception of "natural meets pharmaceutical-grade" continues to gain traction, omega-3 drugs are bridging the gap between traditional pharmacotherapy and wellness-centric, patient-preferred medicine.

What’s Fueling the Accelerated Growth of the Omega-3 Prescription Drugs Market Globally?

The growth in the omega-3 prescription drugs market is driven by several factors rooted in clinical innovation, chronic disease prevalence, regulatory momentum, and shifting healthcare preferences. One of the primary growth drivers is the global rise in cardiovascular and metabolic disorders-such as hyperlipidemia, diabetes, and obesity-which increase demand for adjunctive lipid-lowering therapies that go beyond statins. Additionally, favorable results from landmark studies like REDUCE-IT and JELIS have strengthened the clinical positioning of EPA-focused therapies, prompting widespread adoption in cardiology and internal medicine. The expanding elderly population-especially in North America, Europe, and Japan-is further contributing to demand, given the age-related increase in CVD, cognitive decline, and inflammation-related disorders. On the commercial side, pharmaceutical innovation in formulation technologies and dosage optimization has enhanced drug tolerability, bioavailability, and compliance, leading to improved therapeutic outcomes. Increasing regulatory approvals in emerging markets, coupled with rising insurance coverage and public health campaigns, are also facilitating market penetration. The blurring lines between nutraceuticals and pharmaceuticals have opened doors for pharma-nutrition collaborations and hybrid business models. Moreover, growing awareness of omega-3’s broader benefits-ranging from eye and brain health to joint mobility-is prompting physicians to consider it for holistic treatment plans. Collectively, these dynamics are pushing omega-3 prescription drugs from a niche cardiovascular add-on to a mainstream, multifunctional therapeutic solution across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Omega 3 Prescription Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Vascepa Drugs, Lovaza Drugs, Other Drugs); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); Application (Cardiovascular Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abbott Laboratories
• Amarin Corporation plc
• Apotex Inc.
• AstraZeneca plc
• BASF SE
• Bayer AG
• Camber Pharmaceuticals, Inc.
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc (GSK)
• Grupo Ferrer Internacional, S.A.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
• Novartis International AG
• Pfizer Inc.
• Sandoz International GmbH
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Omega 3 Prescription Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Landmark Cardiovascular Outcomes Trials Spur Growth and Reinforce Clinical Credibility of Omega-3 Prescription Therapies
  • Rising Prevalence of Hypertriglyceridemia and Cardiometabolic Disorders Throws the Spotlight on High-Purity EPA Formulations
  • Here's How Shifting Physician and Payer Preferences Are Driving Adoption of Prescription-Grade Omega-3 Over OTC Supplements
  • Expanding Use in Adjunctive Therapy for Statin-Resistant and High-Risk Cardiovascular Patients Strengthens the Business Case
  • Advancements in Drug Delivery Systems Enhance Bioavailability and Minimize Gastrointestinal Side Effects
  • Growing Geriatric Population with Complex Comorbidities Accelerates Demand for Safe, Long-Term Lipid-Lowering Agents
  • Integration of Omega-3 Therapies in Precision Medicine Initiatives Expands Addressable Patient Populations
  • Here's the Story Behind How Preventive Healthcare Trends Are Driving Prescription Demand in Primary Care Settings
  • Increasing Pharmaceutical Investment in Omega-3 Pipeline Products Spurs Innovation in Formulation and Indication Scope
  • Global Shift Toward Value-Based Care and Outcomes-Driven Prescribing Supports Growth of Efficacious, Low-Risk Omega-3 Drugs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Omega 3 Prescription Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Omega 3 Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Vascepa Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Vascepa Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Vascepa Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lovaza Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lovaza Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Lovaza Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Omega 3 Prescription Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Omega 3 Prescription Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Omega 3 Prescription Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION